Sigyn Therapeutics' Net Loss Widens Amid Zero Revenue, Cash Dwindles

TL;DR

**SIGY is burning cash with no revenue, making it a highly speculative bet on future clinical success that looks increasingly unlikely without immediate, substantial funding.**

AI Summary

Sigyn Therapeutics, Inc. (SIGY) reported a net loss of $2,119,751 for the six months ended June 30, 2025, a significant increase from the $1,620,471 net loss for the same period in 2024. The net loss for the three months ended June 30, 2025, was $1,451,187, up from $862,383 in the prior year. The company generated no net revenues in either period. Operating expenses decreased to $1,015,572 for the six months ended June 30, 2025, from $1,232,774 in 2024, primarily due to a substantial reduction in research and development expenses from $473,022 to $16,323. However, total other expense surged to $1,104,179 for the six months, largely driven by an $845,901 inducement of preferred shares and $17,505 for modification of warrants. Cash balances plummeted from $12,144 at December 31, 2024, to $459 at June 30, 2025, indicating severe liquidity constraints. The company continues to develop medical devices for cancer and infectious diseases, including Sigyn Therapy™ for infectious diseases and ImmunePrep™, ChemoPrep™, and ChemoPure™ for cancer therapies, but faces substantial financial challenges.

Why It Matters

Sigyn Therapeutics' continued lack of revenue and rapidly diminishing cash reserves, down to just $459, signals a critical financial situation for investors. The company's ability to fund its ambitious medical device development, including Sigyn Therapy™ and its cancer platforms, is severely compromised, raising significant going concern doubts. This financial instability could impact employees through potential layoffs and delay or halt the development of potentially life-saving therapies for customers. In a competitive biotech landscape, SIGY's struggle to secure funding and generate income puts it at a distinct disadvantage against larger, better-capitalized players like Fresenius Medical Care and DaVita, Inc., who dominate the dialysis market that SIGY aims to enter.

Risk Assessment

Risk Level: high — The company's cash balance decreased from $12,144 at December 31, 2024, to a mere $459 at June 30, 2025, representing a 96.2% decline. This, coupled with a net loss of $2,119,751 for the six months ended June 30, 2025, and zero net revenues, indicates severe liquidity issues and a high risk of business failure without significant capital infusion.

Analyst Insight

Investors should exercise extreme caution and consider divesting any holdings in SIGY. The company's dire cash position and consistent net losses without any revenue generation suggest a high probability of further dilution or bankruptcy. New investment is highly speculative and not recommended given the current financial instability.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$2,119,751

eps

-$1.32

gross Margin

N/A

cash Position

$459

revenue Growth

N/A

Revenue Breakdown

Key Numbers

• $2,119,751 — Net Loss (For the six months ended June 30, 2025, an increase from $1,620,471 in 2024.)
• $459 — Cash (As of June 30, 2025, a decrease from $12,144 at December 31, 2024.)
• $0 — Net Revenues (For the three and six months ended June 30, 2025 and 2024.)
• $16,323 — Research and Development Expenses (For the six months ended June 30, 2025, a significant decrease from $473,022 in 2024.)
• $845,901 — Inducement of Preferred Shares (A major component of other expense for the six months ended June 30, 2025.)
• $1,104,179 — Total Other Expense (For the six months ended June 30, 2025, up from $387,697 in 2024.)
• 1,605,377 — Shares of Common Stock Outstanding (As of September 5, 2025.)
• $1.32 — Net Loss Per Share (For the six months ended June 30, 2025, compared to $1.31 in 2024.)
• $5,437,629 — Total Stockholders' Deficit (As of June 30, 2025, an increase from $4,457,624 at December 31, 2024.)
• $446,882 — Net Cash Used in Operating Activities (For the six months ended June 30, 2025.)

Key Players & Entities

• Sigyn Therapeutics, Inc. (company) — Registrant and medical device developer
• Fresenius Medical Care (company) — Dominant player in the North American dialysis industry
• DaVita, Inc. (company) — Dominant player in the North American dialysis industry
• FDA (regulator) — Regulatory authority for medical devices and drug approvals
• Ebola (disease) — Infectious viral pathogen for which management previously developed a device with Emergency Use Authorization
• TIME Magazine (publication) — Named a device developed by management to its 'Top Inventions' list in 2015
• ImmunePrep™ (product) — Platform to enhance immunotherapeutic antibodies
• ChemoPrep™ (product) — Device to improve chemotherapy delivery
• ChemoPure™ (product) — Device to reduce chemotherapy toxicity
• Sigyn Therapy™ (product) — Lead therapeutic candidate for infectious disease disorders

FAQ

Risk Factors

• Severe Liquidity Constraints [high — financial]: Cash balance decreased from $12,144 at December 31, 2024, to $459 at June 30, 2025. This severe reduction in cash indicates significant financial distress and potential inability to meet ongoing operational needs.
• Increasing Net Losses [high — financial]: Net loss for the six months ended June 30, 2025, was $2,119,751, an increase from $1,620,471 in the prior year. The net loss for the three months ended June 30, 2025, was $1,451,187, up from $862,383 in the prior year, indicating deteriorating profitability.
• Significant Other Expenses [medium — financial]: Total other expense surged to $1,104,179 for the six months ended June 30, 2025, driven by an $845,901 inducement of preferred shares and $17,505 for modification of warrants. These non-operational expenses significantly impacted the net loss.
• Dependence on Product Development [high — operational]: The company continues to develop medical devices for cancer and infectious diseases, including Sigyn Therapy™, ImmunePrep™, ChemoPrep™, and ChemoPure™. However, the lack of revenue generation suggests significant hurdles in commercialization and market adoption.
• Deteriorating Stockholders' Deficit [medium — financial]: Total stockholders' deficit increased to $5,437,629 as of June 30, 2025, from $4,457,624 at December 31, 2024. This indicates that liabilities exceed assets, a sign of financial weakness.
• High Net Loss Per Share [medium — financial]: The net loss per share for the six months ended June 30, 2025, was $1.32, a slight increase from $1.31 in the prior year. This reflects the growing losses relative to the outstanding shares.

Industry Context

Sigyn Therapeutics operates in the highly competitive and capital-intensive biotechnology and medical device sectors, focusing on cancer and infectious diseases. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory approval processes. Companies often rely on substantial funding rounds and partnerships to advance their pipelines.

Regulatory Implications

As a developer of medical devices, Sigyn Therapeutics is subject to rigorous oversight by regulatory bodies such as the FDA. The company must navigate complex approval pathways for its products, and any delays or failures in obtaining regulatory clearance could severely impact its ability to generate revenue and achieve commercial success.

What Investors Should Do

1. Monitor cash burn and future funding needs.
2. Evaluate the commercial viability of product pipeline.
3. Analyze the impact of non-operational expenses.

Key Dates

• 2025-06-30: End of Second Quarter 2025 — Reported a net loss of $1,451,187 for the quarter and $2,119,751 for the six months, with cash balance reduced to $459.
• 2024-12-31: End of Fiscal Year 2024 — Cash balance was $12,144, indicating a substantial decrease in liquidity by mid-2025.

Glossary

Inducement of Preferred Shares

Shares issued to a party as an incentive or compensation, often in connection with a transaction or agreement. (A significant expense of $845,901 in the six months ended June 30, 2025, contributed heavily to the total other expense and net loss.)

Modification of Warrants

Changes made to the terms or conditions of outstanding warrants, which can result in a revaluation and potential expense. (An expense of $17,505 was recorded for warrant modification in the six months ended June 30, 2025, adding to other expenses.)

Stockholders' Deficit

A situation where a company's total liabilities exceed its total assets, resulting in a negative equity position. (Sigyn Therapeutics has a stockholders' deficit of $5,437,629 as of June 30, 2025, indicating a negative net worth.)

Year-Over-Year Comparison

Compared to the prior year's six-month period, Sigyn Therapeutics has seen a substantial increase in its net loss, rising from $1,620,471 to $2,119,751. While operating expenses decreased due to a sharp reduction in R&D spending, this was offset by a significant surge in other expenses, primarily from preferred share inducements. Most critically, the company's cash position has deteriorated dramatically, falling from $12,144 to just $459, signaling severe liquidity concerns.

Key Financial Figures

• $0.0001 — ction 12(g) of the Act: Common Stock, $0.0001 Par Value Indicate by check mark whet

Filing Documents

• form10-q.htm (10-Q) — 1265KB
• ex31-1.htm (EX-31.1) — 11KB
• ex32-1.htm (EX-32.1) — 7KB
• 0001641172-25-026704.txt ( ) — 5881KB
• sigy-20250630.xsd (EX-101.SCH) — 37KB
• sigy-20250630_cal.xml (EX-101.CAL) — 44KB
• sigy-20250630_def.xml (EX-101.DEF) — 154KB
• sigy-20250630_lab.xml (EX-101.LAB) — 345KB
• sigy-20250630_pre.xml (EX-101.PRE) — 278KB
• form10-q_htm.xml (XML) — 974KB

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION 4 Item 1.

Financial Statements

Financial Statements 4 Unaudited Condensed Consolidated Balance Sheets as of June 30, 2025 and December 31, 2024 4 Unaudited Condensed Consolidated Statements of Operations for the Three and six months ended June 30, 2025 and 2024 5 Unaudited Condensed Consolidated Statements of Stockholders' Deficit for the Three and six months ended June 30, 2025 and 2024 6 Unaudited Condensed Consolidated Statements of Cash Flows for the Six months ended June 30, 2025 and 2024 7 Notes to the Unaudited Condensed Consolidated Financial Statements 8 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 26 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 46 Item 4.

Controls and Procedures

Controls and Procedures 46

– OTHER INFORMATION

PART II – OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 47 Item1A.

Risk Factors

Risk Factors 4 7 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 47 Item 3. Defaults Upon Senior Securities 47 Item 4. Mine Safety Disclosure 48 Item 5. Other Information 48 Item 6. Exhibits 48

SIGNATURES

SIGNATURES 51 2 DISCLOSURE REGARDING FORWARD LOOKING STATEMENTS This report contains forward-looking statements. The forward-looking statements are contained principally in the sections entitled "Description of Business," "Risk Factors," and "Management's Discussion and Analysis of Financial Condition and Results of Operations." These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "anticipates," "believes," "seeks," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "would" and similar expressions intended to identify forward-looking statements. Forward-looking statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: the ability of Sigyn to meet its financial and strategic goals, due to, among other things, competition; the ability of Sigyn to grow and manage growth profitability and retain its key employees; the possibility that the Sigyn may be adversely affected by other economic, business, and/or competitive factors; risks relating to the successful development of Sigyn's product candidates; the ability to successfully complete planned clinical studies of its product candidates; the risk that we may not fully enroll our clinical studies or enrollment will take longer than expected; risks relating to the occurrence of adverse safety events and/or unexpected concerns that may arise from data or analysis from our clinical studies; changes in applicable laws or regulations; expected ini

View Full Filing

View this 10-Q filing on SEC EDGAR